Prof. Gabriela Kramer-Marek leads translational imaging research at the Institute of Cancer Research (ICR), London, and the National Oncology Institute (NIO) in Gliwice, Poland. She heads the Preclinical Molecular Imaging Group at ICR and the Department of Radiopharmacy and Preclinical PET Imaging at NIO, where she develops and translates molecular imaging approaches for cancer, with a focus on glioblastoma and breast cancer.
She holds a PhD in Medical Physics from the Silesian University of Technology and completed postdoctoral training at the National Cancer Institute (NIH, USA). Her work has contributed to the development of imaging strategies based on antibodies and affibody molecules, including early clinical studies using zirconium-89-labelled agents in glioblastoma to assess response to neoadjuvant therapy.
Her current research focuses on imaging biomarkers of treatment response and resistance, as well as the development of radioligand therapy approaches for glioblastoma. She leads multidisciplinary teams working across radiochemistry, biology and imaging, with a strong emphasis on translating preclinical findings into clinical applications.
